Shares of SRAD are declining approximately 10.27% on Tuesday, April 28, 2026, falling from a prior close of $13.93 to approximately $12.50, as the compound effect of Muddy Waters' short-seller allegations, Callisto Capital's corroborating accusations, multiplying class action securities fraud lawsuits, and a Q1 2026 revenue pre-announcement at the low end of investor expectations overwhelms the modest bounce that briefly stabilized the stock on April 27.
MU stock surged +47% over the last 30 days, recovering sharply from a post-earnings dip amid strong analyst support and AI-driven demand. Over the past quarter, shares rose +21%, fueled by record fiscal Q2 results but marked by volatility from profit-taking and capital expenditure concerns.
XOM stock declined 13% over the past 30 days amid falling oil prices following eased geopolitical tensions in the Middle East. Over the past quarter, shares rose 8% driven by an earlier oil price rally fueled by regional conflicts and strong upstream performance.
NVDA stock surged +31% over the past 30 days, driven by renewed investor confidence in sustained AI chip demand and positive analyst sentiment. Over the past quarter, shares rose +13%, reflecting volatility with early dips offset by strong recovery on AI catalysts like new platform launches.
NKE stock declined approximately -12% over the past 30 days, driven primarily by a post-earnings sell-off following weak fiscal Q4 sales guidance. Over the past quarter, shares fell around -27%, amid broader challenges including weakness in China and declining consumer demand in athletic apparel.
TT stock surged +18% over the past 30 days, driven by anticipation ahead of Q1 earnings and sustained momentum from prior strong results. Over the past quarter, shares climbed +23%, fueled by a Q4 earnings beat with record bookings and robust revenue growth.
CM stock rose +17% over the past 30 days, driven by positive analyst upgrades and momentum from strong quarterly results. Over the past quarter, shares gained +19%, reflecting resilient earnings beats and dividend increases amid economic uncertainty.
CVS Health stock rose approximately +12% over the last 30 days, rebounding from late-March lows around $70 amid positive market sentiment and sector outperformance. Over the past quarter, shares gained +12%, supported by a strong Q4 2025 earnings beat despite intra-quarter volatility.
GLW shares are declining approximately 7.00% in Tuesday's session, falling from a prior close of $168.01 to approximately $156.25 intraday. The primary catalyst is a mixed Q1 2026 earnings report: GAAP EPS of $0.43 missed the $0.59 consensus estimate by 27%, and GAAP revenue of $4.14 billion fell short of the $4.26 billion estimate.
NVTS shares are declining approximately 13.00% in Tuesday's session, falling from a prior close of $18.30 to approximately $15.92 intraday. The primary catalyst is a Rosenblatt analyst downgrade to Neutral, with a $12 price target, warning that market expectations surrounding Navitas's 800V DC AI data center opportunity are "well ahead of the market".
ERAS shares are down approximately 47.26% in Tuesday's session, falling from a prior close of $19.15 to approximately $10.10 intraday. The primary catalyst is the disclosure of a treatment-related patient death buried within the otherwise positively framed preliminary Phase 1 data release for lead drug candidate ERAS-0015.
RMBS shares are down approximately 21.08% in Tuesday's session, falling from a prior close of $158.40 to around $125.01 intraday. The primary catalyst is a classic "buy the rumor, sell the news" reaction: the stock had surged 76.5% in the month leading into earnings, setting an impossibly high expectations bar.
VISN shares dropped approximately 50.49% in Tuesday's session, falling from a prior close of $19.53 to approximately $9.67 intraday. The decline is a mechanical, dividend-driven price adjustment: today, April 28, 2026, is the ex-dividend date for a special cash distribution of $10.00 per share.
SPOT shares dropped approximately 14% in Tuesday's session, erasing nearly $15 billion in market capitalization in a single day. The primary catalyst was a Q2 2026 operating income guidance of €630 million, which fell well short of the analyst consensus of €674.3 million.
Fabrinet's stock rose +24% over the past 30 days, driven by strong demand in optical communications for AI data centers and telecom. Over the past quarter, shares gained +37%, supported by record quarterly revenues and earnings beats.
ONDS stock surged +21% over the last 30 days, rebounding from post-earnings lows around $8.80 to $10.95 amid strong revenue beats and optimistic 2026 guidance. Over the past quarter, shares declined -11% from $12.27, reflecting high volatility with peaks near $15 followed by corrections.
CPAY stock rose +9.8% over the last 30 days, rebounding from late March lows amid reaffirmed guidance and positive partnerships. Over the past quarter, shares declined -1.5%, reflecting volatility after an early post-earnings rally and a strategic asset sale.
DPRO stock rose approximately +24% over the past 30 days, recovering from post-earnings lows amid renewed interest in drone technology. Over the past quarter, shares declined -32%, driven primarily by a sharp selloff following the Q4 earnings miss on earnings per share (EPS).
Fabrinet's stock rose +24% over the past 30 days, driven by strong demand in optical communications for AI data centers and telecom. Over the past quarter, shares gained +37%, supported by record quarterly revenues and earnings beats.
AMKR stock surged +70% over the past 30 days, driven by strong anticipation and results from Q1 earnings, including a significant revenue beat and EPS (earnings per share) surprise. Over the past quarter, shares rose +48%, reflecting robust semiconductor demand, Q4 earnings beat, and a new $300 million share buyback authorization.